Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

The OPTimization of interferon for MS study: 375 microg interferon beta-1b in suboptimal responders.
Reviewing the Unmet Needs of Patients with Multiple Sclerosis.
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study.
Diffusely abnormal white matter in multiple sclerosis: further histologic studies provide evidence for a primary lipid abnormality with neurodegeneration.
Receptos to deliver scientific presentations about RPC1063 at the 28th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)
The Effect of Glatiramer Acetate Therapy on Functional Properties of B Cells From Patients With Relapsing-Remitting Multiple Sclerosis.
Complexity of trophic factor signaling in experimental autoimmune encephalomyelitis: Differential expression of neurotrophic and gliotrophic factors.
What Explains Gray Matter Atrophy in Long-standing Multiple Sclerosis?
Rituximab, an anti-CD20 monoclonal antibody: History & mechanism: Off label rituximab use in transplant patients
Trimesta in relapsing-remitting multiple sclerosis patients (Phase II)
Tcelna® (imilecleucel-T)
FDA approval letter for daclizumab for the prophylaxis of acute organ rejection in patients receiving renal transplants
Betaseron 16-Year Long-Term Follow-Up (LTF) in Patients With Relapsing-Remitting Multiple Sclerosis
NQO1-dependent redox cycling of idebenone: effects on cellular redox potential and energy levels.
Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study.
Corpus callosum atrophy is strongly associated with cognitive impairment in multiple sclerosis: Results of a 17-year longitudinal study.
Varicella zoster-associated retinal and central nervous system vasculitis in a patient with multiple sclerosis treated with natalizumab.
Biogen Idec's long-acting beta interferon moves ahead in MS
The topograpy of demyelination and neurodegeneration in the multiple sclerosis brain.
Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study.
The prediction of human response to ONO-4641, a sphingosine 1-phosphate receptor modulator, from preclinical data based on pharmacokinetic-pharmacodynamic modeling.
Radiologic MS disease activity during natalizumab treatment interruption: findings from RESTORE.
Oxidative modification of serum proteins in multiple sclerosis.
Nasal administration of drugs as a new non-invasive strategy for efficient treatment of multiple sclerosis.
Ofatumumab Subcutaneous Administration in Subjects With Relapsing-Remitting Multiple Sclerosis (MIRROR)

Pages